Male contraceptive drugs DMAU and 11 beta-MNTDC effectively reduce testosterone without causing unacceptable side effects, says a new study.
The drugs, called DMAU and 11 beta-MNTDC, are part of a class of drugs called progestogenic androgens. These drugs suppress testosterone, which lowers sperm count.
Male Contraception: New Findings
“Male contraception options are currently restricted to vasectomy and condoms and are thus extremely limited as compared to female options,” said lead researcher Tamar Jacobsohn of the Contraceptive Development Program at the Eunice Kennedy Shriver National Institute of Child Health and Human Development.
‘Lowering testosterone levels normally leads to unpleasant side effects, but most of the men in the study were willing to continue using the drugs, suggesting the side effects were acceptable.’
“Development of an effective, reversible male contraceptive method will improve reproductive options for men and women, have a major impact on public health by decreasing unintended pregnancy, and allow men to have an increasingly active role in family planning,” Jacobsohn added.
For the study to be presented at ENDO 2022, the team included 96 healthy male participants in two Phase 1 clinical trials. In each trial, the men were randomly assigned to receive two or four oral pills of active drug or placebo daily for 28 days.
After seven days on the active drug, testosterone levels dropped below the normal range. In men taking the placebo, testosterone levels stayed within the normal range.
The study found that 75% of men who took the active drug said they would be willing to use it in the future, compared with 46.4% of those taking a placebo.
Men who took the four-pill daily dose (400 milligrams) had lower testosterone levels than those taking the two-pill, 200-milligram dose.
There was no significant difference between the two active treatment groups regarding satisfaction with the drug or willingness to use it in the future or recommend it to others.